CEP-9722 (paralog cep-8983) is also a PARP inhibitor, which is currently in phase I clinical trial for the treatment of MCL in combination with gemcitabine and cisplatin [ClinicalTrials.gov Identifier: NCT01345357]. This evidence concerns the gene PARP1 and mantle cell lymphoma.